Pulmonary Arterial Hypertension (PAH) is a progressive and fatal disease characterized by increased pulmonary vascular resistance and right heart failure. The modern management of PAH relies heavily on a goal-oriented treatment strategy driven by regular risk assessment. This article presents a prospective clinical study conducted at the Department of Faculty Therapy of Andijan State Medical Institute. Using the IMRAD framework, the research evaluates the prognostic value of the multiparametric risk stratification strategy recommended by ESC/ERS guidelines in 54 patients with idiopathic and connective tissue disease-associated PAH. The study correlates risk strata (low, intermediate, high) with clinical outcomes and novel metabolic markers. The results demonstrate that patients maintaining a low-risk profile exhibit significantly better survival and functional capacity, while intermediate and high-risk status is associated with metabolic derangement and frequent hospitalization. The study concludes that rigorous, dynamic risk stratification is the cornerstone of effective PAH management in the local population.

pulmonary arterial hypertension, risk stratification, right heart failure, prognosis, multiparametric assessment, metabolic markers.

Humbert, M., Kovacs, G., Hoeper, M. M., et al. (2022). 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 43(39), 3618-3731.

Galie, N., Channick, R. N., Frantz, R. P., et al. (2015). Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal, 46(6), 1796-1808.

Boucly, A., Weatherald, J., Savale, L., et al. (2017). Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 50(2), 1700889.

Kylhammar, D., Kjellstrom, B., Hjalmarsson, C., et al. (2018). A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. European Heart Journal, 39(47), 4175-4181.

Sitbon, O., Gomberg-Maitland, M., Granton, J., et al. (2019). Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal, 53(1), 1801908.

Hoeper, M. M., Pausch, C., Olsson, K. M., et al. (2022). COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal, 60(1), 2102311.

Weatherald, J., Boucly, A., Chemla, D., et al. (2018). Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation, 137(7), 693-704.

Tashtemirova, I. M. (2024). ON THE STATE OF FUNCTIONAL ACTIVITY OF THE SYMPATHETIC-ADRENAL SYSTEM AND FREE RADICAL PROCESSES IN WOMEN OF FERTILE AGE WITH METABOLIC SYNDROME.

Juraboyev, X. O., & Tashtemirova, I. M. (2025). ASSESSMENT OF LIPID PEROXIDATION PROCESSES AND LIPID METABOLISM DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE UNDERGOING COMBINED HYPOLIPIDEMIC THERAPY. INTERNATIONAL JOURNAL OF SOCIAL SCIENCE & INTERDISCIPLINARY RESEARCH, 14(07), 20-23.

Tashtemirova, I. M. (2025). DIAGNOSTIC CRITERIA AND ATTENTIVE REVIEWS IN THE TREATMENT OF CARDIAC X SYNDROME ANICIZED PATIENTS. INTERNATIONAL JOURNAL OF SOCIAL SCIENCE & INTERDISCIPLINARY RESEARCH, 14(07), 29-32.